Alexion
Alexion’s Soliris successor aces two phase 3 trials
Alexion, R&D, Rare diseases
0 Comment
But Alexion shares hit by EU patent ruling
Alexion bids $855m for rare disease biotech Wilson Therapeutics
Alexion, M&A, Rare diseases
0 Comment
Wilson’s board has unanimously accepted the offer
Alexion to file successor to rare diseases drug Soliris
Alexion, Rare diseases, Soliris
0 Comment
New drug is in patient-friendly subcutaneous form
Myasthenia Gravis approval will boost Soliris revenues
Alexion, myasthenia gravis, Rare diseases, Soliris
0 Comment
Alexion cuts ties with Moderna and re-focuses
Alexion, Rare diseases
0 Comment
Alexion cuts collaborations with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma
NHS supremo hails Alexion and Roche deals, but defends budget controls
Alexion, BIA, Brexit, Budget Impact Test, MHRA, NHS England, Simon Stevens
0 Comment
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
Alexion price cut opens up Strensiq to more patients
Alexion, market access, NICE, ultra-rare diseases
0 Comment
Managed access scheme will control costs to NHS.